category,datetime,headline,id,image,related,source,summary,url
company,1756741800,ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win,136605164,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,ALNY,Yahoo,"Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study.",https://finnhub.io/api/news?id=1a04897aecf189860f766195046615c97b3bd67d2ea8c624244c1b9edfa88b92
company,1756567800,Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial,136596930,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,ALNY,Yahoo,"CAMBRIDGE, Mass., August 30, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC)",https://finnhub.io/api/news?id=7b4cc42881bb831c982bf316409461173049b501fad76e8fc4a255f8d670703a
company,1756567800,Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension,136596929,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,ALNY,Yahoo,"Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3In the Phase II KARDIA-3 study, presented today as a late breaker at the European Society of Cardiology Congress 2025, zilebesiran demonstrated clinically meaningful reductions in office systolic blood pressure at month three with continuous control through month sixZilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing,",https://finnhub.io/api/news?id=10081b98f0cc032e7014cbc590aea45899adc76274cff5c0d998764e5647d10f
company,1756567800,Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension,136596928,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,ALNY,Yahoo,"SOUTH SAN FRANCISCO, Calif., August 30, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam (Nasdaq: ALNY) today announced the decision to initiate a Phase III cardiovascular outcomes trial (CVOT) to evaluate the ability of zilebesiran, an RNAi therapeutic, to reduce the risk of major adverse cardiovascular events in patients with uncontrolled hypertension. This decision was informed by the comprehensive KARDIA Phase II program, including KARDIA-1, KARDIA-2 and",https://finnhub.io/api/news?id=66173dfa0d7190e3781fd8499e69005e5da9cc413b48a15c732f0a906015c346
